According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (KYMR -0.86%) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile biotech sector. Investors were cheered by a pair of announcements published by the company. Patients dosed in early-stage trialKymera is a clinical-stage biotech that specializes in a mechanism known as targeted protein degradation in its medicines. On Tuesday, the company delivered encouraging news from the labo ...